These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36856394)

  • 1. Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as "toxic epidermal necrolysis-like".
    Eldani C; Darrigade AS; Beylot-Barry M; Jullie ML; Ducharme O; Milpied B; Pham-Ledard A
    Eur J Dermatol; 2022 Nov; 32(6):805-807. PubMed ID: 36856394
    [No Abstract]   [Full Text] [Related]  

  • 2. Toxic epidermal necrolysis associated with pembrolizumab.
    Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
    Hwang A; Iskandar A; Dasanu CA
    J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
    Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
    R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction.
    Neema S; Sathu S; Vasudevan B; Shreshta S; Bhatt S; K L
    Indian J Dermatol Venereol Leprol; 2023; 89(4):589-591. PubMed ID: 37067146
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy.
    Lomax AJ; McQuillan PIA; Hall A; McArthur GA
    Intern Med J; 2019 Aug; 49(8):1051-1053. PubMed ID: 31387152
    [No Abstract]   [Full Text] [Related]  

  • 7. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
    Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
    Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction.
    Shi CR; Shaughnessy M; Sehgal K; Clark JR; Reynolds KL; Toyohara J; Chen ST
    Int J Dermatol; 2023 Oct; 62(10):1292-1294. PubMed ID: 36628976
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bullous drug reaction after pembrolizumab administration: two case reports].
    Golle L; Michl C; Kreft B
    Dermatologie (Heidelb); 2022 Dec; 73(12):959-964. PubMed ID: 35925211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
    Robinson S; Saleh J; Curry J; Mudaliar K
    Am J Dermatopathol; 2020 Apr; 42(4):292-296. PubMed ID: 31567395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab induced toxic epidermal necrolysis.
    Kumar R; Bhandari S
    Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
    [No Abstract]   [Full Text] [Related]  

  • 12. A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment.
    Oguri T; Sasada S; Shimizu S; Shigematsu R; Tsuchiya Y; Ishioka K; Takahashi S; Oki K; Kimura Y; Seki R; Hirose S; Nakamura M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211037462. PubMed ID: 34344201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
    Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP
    Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Antoon JW; Goldman JL; Lee B; Schwartz A
    Pediatr Dermatol; 2018 Mar; 35(2):182-187. PubMed ID: 29315761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
    Ririe MR; Blaylock RC; Morris SE; Jung JY
    J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.
    Frey N; Bodmer M; Bircher A; Jick SS; Meier CR; Spoendlin J
    Drug Saf; 2019 Jan; 42(1):55-66. PubMed ID: 30112729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.
    Auquier-Dunant A; Mockenhaupt M; Naldi L; Correia O; Schröder W; Roujeau JC;
    Arch Dermatol; 2002 Aug; 138(8):1019-24. PubMed ID: 12164739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
    Xu C; Pan L; Zhang Y; Zhang J; Sun Q; Fang W
    Int J Clin Pract; 2021 Aug; 75(8):e14273. PubMed ID: 33908133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.